NICE consults on a new treatment for prostate cancer

NICE consults on a new treatment for prostate cancer: NICE, the healthcare guidance body, has issued new draft guidance not recommending the use of abiraterone (Zytiga, Janssen) in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer that has progressed on or after docetaxel-containing therapy.